Dexcom (DXCM) Shares Outstanding (Weighted Average) (2016 - 2025)
Dexcom (DXCM) has disclosed Shares Outstanding (Weighted Average) for 16 consecutive years, with $390.2 million as the latest value for Q4 2025.
- Quarterly Shares Outstanding (Weighted Average) fell 0.86% to $390.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $390.2 million through Dec 2025, down 0.86% year-over-year, with the annual reading at $390.2 million for FY2025, 0.86% down from the prior year.
- Shares Outstanding (Weighted Average) for Q4 2025 was $390.2 million at Dexcom, roughly flat from $391.1 million in the prior quarter.
- The five-year high for Shares Outstanding (Weighted Average) was $399.2 million in Q2 2024, with the low at $96.3 million in Q1 2021.
- Average Shares Outstanding (Weighted Average) over 5 years is $375.2 million, with a median of $389.8 million recorded in 2022.
- The sharpest move saw Shares Outstanding (Weighted Average) skyrocketed 316.92% in 2021, then dropped 1.78% in 2025.
- Over 5 years, Shares Outstanding (Weighted Average) stood at $386.9 million in 2021, then grew by 0.65% to $389.4 million in 2022, then dropped by 0.87% to $386.0 million in 2023, then increased by 1.97% to $393.6 million in 2024, then fell by 0.86% to $390.2 million in 2025.
- According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $390.2 million, $391.1 million, and $392.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.